This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Halozyme Therapeutics Inc (HALO)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -68.38M -83.48M -53.55M -19.77M
Operating Gains/Losses 233.00K 0.00 7.37K -1.57K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -52.00K 6.61M -13.44M 65.80K
(Increase) Decrease in Inventories -236.00K -3.50M -2.10M -373.84K
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -816.00K 7.89M -3.26M 711.78K
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 1.48M 9.15M 3.01M -17.04M
Other Non-Cash Items 17.30M 9.69M 8.36M 5.57M
Net Cash From Continuing Operations -47.52M -49.34M -64.33M -34.35M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -47.52M -49.34M -64.33M -34.35M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 57.30M 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -1.37M -2.30M -1.41M -828.51K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -88.88M 0.00 0.00 0.00
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -32.95M -47.87M -1.41M -828.51K
Issuance of Debt 0.00 19.99M 29.66M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 114.50M 5.08M 83.16M 4.75M
Repayment of Long-Term Debt 0.00 0.00 0.00 0.00
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 0.00 0.00 0.00 0.00
Net Cash From Financing Activities 114.50M 25.06M 112.82M 4.75M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 34.03M -72.14M 47.08M -30.43M

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

HALO Halozyme Therapeutics Inc

Chart of HALO

Analysts Ratings for HALO

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 3 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0

HALO Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs